You are currently browsing the archives for the Bio-Rad Product Highlight category.

Archive for the ‘Bio-Rad Product Highlight’ Category

Purifying Untagged Protein With Ease

 :: Posted by American Biotechnologist on 02-10-2014

High purity protein is a common requirement for biochemical and structural studies. A common approach is to recombinantly express an affinity-tagged version of the protein of interest. This is, however, not always a viable option. Some proteins are unstable or inactive once tagged or require posttranslational modifications that do not permit recombinant expression. In these cases, researchers often settle for lower purity protein rather than exhaustively explore purification options, since the purification optimization process can be time and labor intensive when no particular column resins or buffer conditions are dictated by an affinity tag.

Bio-Rad Laboratories has recently released a study demonstrating how to purify untagged protein to high homogeneity without undergoing laborious manual troubleshooting steps. Bio-Rad’s ChromLab software can be programmed to execute several runs sequentially thereby automating and accelerating this tedious process.

To learn how to purify untagged protein with ease read Protein Purification Workflow Development Using Bio-Rad’s NGC™ Chromatography System.

Using Droplet Digital™ PCR to Diagnose Leukemia

 :: Posted by American Biotechnologist on 01-20-2014

Bio-Rad Offers New PrimePCR™ Disease Panels for Real-Time PCR

 :: Posted by American Biotechnologist on 12-18-2013

Bio-Rad Laboratories announced the launch of more than 700 new PrimePCR human and mouse disease panels and 71 new pathway panels for real-time PCR (qPCR). The panels allow researchers to thoroughly and efficiently investigate genes known to be differentially expressed in a specified pathology or biological pathway. Bio-Rad now offers more than 1,100 panels with nearly 6,700 predesigned plate configurations, establishing Bio-Rad as the industry’s largest and most up-to-date provider of predesigned plates.

The expanded product line includes highly studied pathways such as Hedgehog and bone morphogenetic protein (BMP) signaling, as well as processes such as circadian rhythms and visual perception. In addition, disease categories span hundreds of conditions, ranging from specific cancers and neoplasms to metabolic diseases such as obesity and diabetes.

Working in collaboration with Thomson Reuters, Bio-Rad developed a plate design strategy that ensures that the most relevant gene targets are chosen for each real-time PCR panel; gene targets are weighted for differentially expressed genes and the frequency with which they appear in the peer-reviewed literature. For disease panels, Thomson Reuters referenced the diseases and their corresponding gene targets in the U.S. National Library of Medicine database.

All of the assays were designed strictly adhering to MIQE guidelines: maximum transcript coverage, minimal overlap with known single nucleotide polymorphisms, and spanning large introns where possible. In addition, all of the primer assays have been fully wet-lab validated for specificity, efficiency, and sensitivity to an unprecedented level of quality, according to Jan Hellemans, cofounder of the qPCR and bioinformatics firm Biogazelle, which worked with Bio-Rad to develop these assays.

Bio-Rad has also updated and expanded its existing predesigned pathway and collection panels to include the most scientifically relevant gene targets based on current literature and the latest bioinformatics data.

For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCR.

Bio-Rad Launches PrimePCR™ Assays for Droplet Digital™ PCR

 :: Posted by American Biotechnologist on 12-11-2013

Bio-Rad Laboratories, Inc. announced the release of its PrimePCR assays for Droplet Digital PCR systems. This release expands Bio-Rad’s current offering by an additional 46 mutation detection assays and 323 copy number assays. In addition, the existing set of gene expression qPCR primer-only assays can now be used with the recently launched QX200™ Droplet Digital PCR system, featuring EvaGreen detection capabilities.

The new ddPCR assays are the only predesigned and fully wet-lab validated assays for digital PCR, alleviating the burden placed on researchers of design and experimental optimization and offering precision and sensitivity without a standard curve. The assays enable novel research strategies and accelerate discovery for inherited disorders, cancer, and infectious diseases.

Many methods for mutation analysis offer poor selectivity and fail to detect mutation events with abundances of less than one in 100 wild-type sequences. Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules, and together with the PrimePCR mutation detection assays, can enable the detection of one mutant molecule in the background of 100,000 wild-type sequences (0.001%). Measuring these extremely low levels of mutation abundance can lead to dramatically more sensitive and less invasive diagnostics.

Current methods, including qPCR and next-generation sequencing, also lack the resolution needed to accurately analyze copy number variation (CNV). Due to their high precision and absolute measurement capability, ddPCR assays enable the quantitative discrimination required to resolve small-fold changes in gene copy numbers. ddPCR assays can also be used to detect subsequent changes in the expression of target genes.

PrimePCR ddPCR assays are available in multiple reaction sizes and are compatible with both the QX100 and QX200 platforms using the ddPCR supermix for probes.

For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCR.

Using Droplet Digital™ PCR to Quantify Levels of HIV Reservoirs

 :: Posted by American Biotechnologist on 12-04-2013